225Ac/177Lu-DOTATATE PRRT治疗进展性脑膜瘤的初步评估:疗效、剂量学与影像学见解
本试点研究纳入7例无法手术或难治性且68Ga-DOTATATE PET/CT高表达SSTR的脑膜瘤患者,接受225Ac-DOTATATE与177Lu-DOTATATE联合或序贯PRRT,中位4周期。主要终点6个月PFS率为85.7%(95%CI 42.1%-99.6%),中位OS 14个月(95%CI 8-18月),仅见1级血液学毒性。
要点
- 联合α/β核素PRRT在进展性脑膜瘤中6个月PFS率达85.7%。
- 中位OS为14个月,临床缓解包括1例完全缓解和2例部分缓解。
- 毒性仅轻度1级血液学毒性,耐受性良好。
核心结论
- 225Ac/177Lu-DOTATATE联合PRRT在晚期脑膜瘤中可行且可能获益。
- 因样本量小、治疗异质性和缺乏对照,结论需谨慎解读。
研究设计与样本
- 试点研究纳入7例无法手术或难治性、68Ga-DOTATATE PET/CT高表达SSTR的脑膜瘤患者。
- 患者接受中位4周期225Ac-DOTATATE与177Lu-DOTATATE联合PRRT,1例仅接受225Ac-DOTATATE。
- 主要终点为治疗后6个月PFS(RANO标准),次要终点包括OS、临床缓解、影像缓解和毒性。
主要发现
- 6个月PFS率为85.7%(95%CI 42.1%-99.6%)。
- 7例中1例完全临床缓解、2例部分缓解、3例稳定。
- 中位OS为14个月(95%CI 8-18月)。
- 病灶水平(n=25)SUVmax显示4个病灶部分缓解、19个稳定、2个进展。
- 仅见轻度1级血液学毒性。
关键数值与推荐
- 单病灶剂量学:225Ac-DOTATATE肿瘤吸收剂量3.36 Gy/MBq,177Lu-DOTATATE为2.37 Gy/GBq。
- 影像缓解采用RANO标准评估。
临床怎么用
- 对于SSTR高表达的进展性难治性脑膜瘤,可考虑225Ac/177Lu-DOTATATE PRRT作为潜在治疗选择。
- 治疗前需68Ga-DOTATATE PET/CT确认高SSTR表达。
局限性
- 样本量小(7例)。
- 治疗异质性(联合或序贯、1例单药)。
- 缺乏对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progressive meningiomas present a significant therapeutic challenge; there are few therapeutic options in this scenario. Peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors (SSTRs) is a promising strategy. This study, for the first time, evaluates the efficacy and safety of a combination or sequential use of alpha- emitting [ 225 Ac]Ac-DOTATATE and beta-emitting [ 177 Lu]Lu-DOTATATE PRRT for patients with advanced, refractory meningiomas. PATIENTS AND METHODS: In this pilot study, 7 patients with inoperable or refractory meningiomas and high SSTR expression on [ 68 Ga]Ga-DOTATATE PET/CT were included. Patients received a median of 4 PRRT cycles, combining [ 225 Ac]Ac-DOTATATE and [ 177 Lu]Lu-DOTATATE. One patient received only 225 Ac-DOTATATE. The primary endpoint was progression-free survival (PFS) at 6 months following treatment using Response Assessment in Neuro-Oncology (RANO) criteria. Secondary endpoints included overall survival (OS), clinical response, imaging response, and toxicity. Imaging response was further assessed through semiquantitative analysis of pretreatment and posttreatment MRI and PET images. Single-lesion dosimetry was performed for 1 patient. RESULTS: Our study achieved a PFS-6 rate of 85.7% (95% CI: 42.1%-99.6%). Of the 7 patients, 1 achieved complete clinical remission, 2 had partial remission, and 3 had stable disease. A median OS of 14 months (95% CI: 8-18 mo). At the lesion level (n = 25), responses were heterogeneous; SUVmax revealed partial response in 4 lesions, stable disease in 19, and progressive disease in 2. The therapy was well-tolerated, with only mild, grade 1 hematological toxicities observed. Single-lesion dosimetry calculated a tumor absorbed dose of 3.36 Gy/MBq for [ 225 Ac]Ac-DOTATATE and 2.37 Gy/GBq for [ 177 Lu]Lu-DOTATATE. CONCLUSIONS: Combined PRRT with 225 Ac/ 177 Lu-DOTATATE appears feasible and potentially beneficial option in advanced meningiomas. However, given the small sample size, treatment heterogeneity, and lack of controlled comparison, the findings should be interpreted with caution. Larger prospective studies are warranted.
引用
- Nemati R, Juweid ME, Jafari E, et al. Preliminary Evaluation of 225 Ac/ 177 Lu-DOTATATE PRRT in Progressive Meningiomas : Efficacy, Dosimetry, and Imaging Insights. Clin Nucl Med. 2026. PMID: 42333414. doi:10.1097/RLU.0000000000006536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。